.png)
Oral Antidiabetic Agents Market by Drug Class and Application- Global Industry Analysis & Forecast to 2027
Published On : January 2021 Pages : 157 Category: Pharma & Healthcare Report Code : HC0114603
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Oral Antidiabetic Agents Market By Drug Class (Biguanides, Thiazolidinediones, Dipeptidyl Peptidase IV Inhibitors, α-Glucosidase Inhibitors, Insulin Secretagogues, Amylin Analog, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Others) and Application (Hospitals, Specialty Clinics, Others)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Oral Antidiabetic Agents Markethas encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Oral Antidiabetic Agents are commonly used in the treatment of diabetes mellitus, as they decrease hepatic glucose production, decrease gastrointestinal glucose absorption, and increase target cell insulin sensitivity.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Oral Antidiabetic Agents Market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Turkey
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Novartis AG
- Eli Lilly and Company
- Merck & Co., Inc
- Novo Nordisk A/S
- Johnson & Johnson Services, Inc.
- Teva Pharmaceuticals Pvt Ltd.
- F. Hoffmann-La Roche Ltd.
- Sanofi
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Oral Antidiabetic Agents Market, ByDrug Class, Estimates and Forecast, 2017-2027 ($Million)
o Biguanides
o Thiazolidinediones
o Dipeptidyl Peptidase IV Inhibitors
o α-Glucosidase Inhibitors
o Insulin Secretagogues
o Amylin Analog
o Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
o Glucagon-Like Peptide-1 Receptor Agonists
o Others
· Oral Antidiabetic Agents Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Hospitals
o Specialty Clinics
o Others
· Oral Antidiabetic Agents Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Novartis AG
o Eli Lilly and Company
o Merck & Co., Inc
o Novo Nordisk A/S
o Johnson & Johnson Services, Inc.
o Teva Pharmaceuticals Pvt Ltd.
o F. Hoffmann-La Roche Ltd.
· Oral Antidiabetic Agents Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Oral Antidiabetic Agents Market, By Country
o U.S. Oral Antidiabetic Agents Market
o Canada Oral Antidiabetic Agents Market
o Mexico Oral Antidiabetic Agents Market
o Europe
§ Europe Oral Antidiabetic Agents Market, By Country
o UK Oral Antidiabetic Agents Market
o Germany Oral Antidiabetic Agents Market
o France Oral Antidiabetic Agents Market
o Russia Oral Antidiabetic Agents Market
o Italy Oral Antidiabetic Agents Market
o Rest of Europe Oral Antidiabetic Agents Market
o Asia-Pacific
§ Asia-Pacific Oral Antidiabetic Agents Market, By Country
o China Oral Antidiabetic Agents Market
o Japan Oral Antidiabetic Agents Market
o South Korea Oral Antidiabetic Agents Market
o India Oral Antidiabetic Agents Market
o Southeast Asia Oral Antidiabetic Agents Market
o Rest of Asia-Pacific Oral Antidiabetic Agents Market
o South America
§ South America Oral Antidiabetic Agents Market
o Brazil Oral Antidiabetic Agents Market
o Argentina Oral Antidiabetic Agents Market
o Columbia Oral Antidiabetic Agents Market
o Rest of South America Oral Antidiabetic Agents Market
o Middle East and Africa
§ Middle East and Africa Oral Antidiabetic Agents Market
o Saudi Arabia Oral Antidiabetic Agents Market
o UAE Oral Antidiabetic Agents Market
o Egypt Oral Antidiabetic Agents Market
o Nigeria Oral Antidiabetic Agents Market
o South Africa Oral Antidiabetic Agents Market
o TurkeyOral Antidiabetic Agents Market
o Rest of MEA Oral Antidiabetic Agents Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Oral Antidiabetic Agents Market, By Drug Class
5.1. Introduction
5.2. Global Oral Antidiabetic Agents Revenue and Market Share by Drug Class (2017-2021)
5.2.1. Global Oral Antidiabetic Agents Revenue and Revenue Share by Drug Class (2017-2021)
5.3. Biguanides
5.3.1. Global Biguanides Revenue and Growth Rate (2017-2021)
5.4. Thiazolidinediones
5.4.1. Global Thiazolidinediones Revenue and Growth Rate (2017-2021)
5.5. Dipeptidyl Peptidase IV Inhibitors
5.5.1. Global Dipeptidyl Peptidase IV Inhibitors Revenue and Growth Rate (2017-2021)
5.6. α-Glucosidase Inhibitors
5.6.1. Global α-Glucosidase Inhibitors Revenue and Growth Rate (2017-2021)
5.7. Insulin Secretagogues
5.7.1. Global Insulin Secretagogues Revenue and Growth Rate (2017-2021)
5.8. Amylin Analog
5.8.1. Global Amylin Analog Revenue and Growth Rate (2017-2021)
5.9. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
5.9.1. Global Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Revenue and Growth Rate (2017-2021)
5.10. Glucagon-Like Peptide-1 Receptor Agonists
5.10.1. Global Glucagon-Like Peptide-1 Receptor Agonists Revenue and Growth Rate (2017-2021)
5.11. Others
5.11.1. Global Others Revenue and Growth Rate (2017-2021)
6. Oral Antidiabetic Agents Market, By Applications
6.1. Introduction
6.2. Global Oral Antidiabetic Agents Revenue and Market Share by Applications (2017-2021)
6.2.1. Global Oral Antidiabetic Agents Revenue and Revenue Share by Applications (2017-2021)
6.3. Hospitals
6.3.1. Global Hospitals Revenue and Growth Rate (2017-2021)
6.4. Specialty Clinics
6.4.1. Global Specialty Clinics Revenue and Growth Rate (2017-2021)
6.5. Others
6.5.1. Global Others Revenue and Growth Rate (2017-2021)
7. Oral Antidiabetic Agents Market, By Region
7.1. Introduction
7.2. Global Oral Antidiabetic Agents Revenue and Market Share by Regions
7.2.1. Global Oral Antidiabetic Agents Revenue by Regions (2017-2021)
7.3. North America Oral Antidiabetic Agents by Countries
7.3.1. North America Oral Antidiabetic Agents Revenue and Growth Rate (2017-2021)
7.3.2. North America Oral Antidiabetic Agents Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Oral Antidiabetic Agents by Countries
7.4.1. Europe Oral Antidiabetic Agents Revenue and Growth Rate (2017-2021)
7.4.2. Europe Oral Antidiabetic Agents Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Oral Antidiabetic Agents by Countries
7.5.1. Asia-Pacific Oral Antidiabetic Agents Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Oral Antidiabetic Agents Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Oral Antidiabetic Agents by Countries
7.6.1. South America Oral Antidiabetic Agents Revenue and Growth Rate (2017-2021)
7.6.2. South America Oral Antidiabetic Agents Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Oral Antidiabetic Agents by Countries
7.7.1. Middle East and Africa Oral Antidiabetic Agents Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Oral Antidiabetic Agents Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Novartis AG
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Eli Lilly and Company
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Merck & Co., Inc
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Novo Nordisk A/S
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Johnson & Johnson Services, Inc.
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Teva Pharmaceuticals Pvt Ltd.
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. F. Hoffmann-La Roche Ltd.
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Sanofi
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
9. Oral Antidiabetic Agents Market Forecast (2022-2027)
9.1. Global Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Oral Antidiabetic Agents Market Forecast by Regions (2022-2027)
9.2.1. North America Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.1.1. United States Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.1.2. Canada Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.1.3. Mexico Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.2. Europe Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.2.1. Germany Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.2.2. France Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.2.3. UK Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.2.4. Russia Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.2.5. Italy Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.3. Asia-Pacific Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.3.1. China Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.3.2. Japan Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.3.3. Korea Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.3.4. India Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.4. South America Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.4.1. Brazil Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.4.2. Argentina Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.4.3. Columbia Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.4.4. Rest of South America Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.5. Middle East and Africa Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.5.3. Egypt Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.5.4. Nigeria Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.5.5. South Africa Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.5.6. Turkey Oral Antidiabetic Agents Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Oral Antidiabetic Agents Market Forecast (2022-2027)
9.3. Oral Antidiabetic Agents Market Forecast by Drug Class (2022-2027)
9.3.1. Oral Antidiabetic Agents Forecast by Drug Class (2022-2027)
9.3.2. Oral Antidiabetic Agents Market Share Forecast by Drug Class (2022-2027)
9.4. Oral Antidiabetic Agents Market Forecast by Applications (2022-2027)
9.4.1. Oral Antidiabetic Agents Forecast by Applications (2022-2027)
9.4.2. Oral Antidiabetic Agents Market Share Forecast by Applications (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Oral Antidiabetic Agents Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Oral Antidiabetic Agents Revenue and Revenue Share by Drug Class (2017-2019)
Figure Global Biguanides Revenue and Growth Rate (2017-2019)
Figure Global Thiazolidinediones Revenue and Growth Rate (2017-2019)
Figure Global Dipeptidyl Peptidase IV Inhibitors Revenue and Growth Rate (2017-2019)
Figure Global α-Glucosidase Inhibitors Revenue and Growth Rate (2017-2019)
Figure Global Insulin Secretagogues Revenue and Growth Rate (2017-2019)
Figure Global Amylin Analog Revenue and Growth Rate (2017-2019)
Figure Global Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Revenue and Growth Rate (2017-2019)
Figure Global Glucagon-Like Peptide-1 Receptor Agonists Revenue and Growth Rate (2017-2019)
Figure Global Others Revenue and Growth Rate (2017-2019)
Table Global Oral Antidiabetic Agents Revenue and Revenue Share by Applications (2017-2019)
Figure Global Hospitals Revenue and Growth Rate (2017-2019)
Figure Global Specialty Clinics Revenue and Growth Rate (2017-2019)
Figure Global Others Revenue and Growth Rate (2017-2019)
Table Global Oral Antidiabetic Agents Revenue by Regions (2017-2019)
Figure North America Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure North America Oral Antidiabetic Agents Revenue and Growth Rate (2017-2019)
Figure North America Oral Antidiabetic Agents by Countries (2017-2019)
Figure North America Oral Antidiabetic Agents Revenue (Million USD) by Countries (2017-2019)
Figure United States Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure United States Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Canada Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Mexico Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Europe Oral Antidiabetic Agents Revenue and Growth Rate (2017-2019)
Figure Europe Oral Antidiabetic Agents by Countries (2017-2019)
Figure Europe Oral Antidiabetic Agents Revenue (Million USD) by Countries (2017-2019)
Figure Germany Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Germany Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure France Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure UK Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Russia Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Italy Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Rest of Europe Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Asia-Pacific Oral Antidiabetic Agents Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Oral Antidiabetic Agents by Countries (2017-2019)
Figure Asia-Pacific Oral Antidiabetic Agents Revenue (Million USD) by Countries (2017-2019)
Figure China Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure China Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Japan Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Korea Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure India Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Southeast Asia Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure South America Oral Antidiabetic Agents Revenue and Growth Rate (2017-2019)
Figure South America Oral Antidiabetic Agents by Countries (2017-2019)
Figure South America Oral Antidiabetic Agents Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Brazil Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Argentina Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Columbia Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Rest of South America Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Middle East and Africa Oral Antidiabetic Agents Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Oral Antidiabetic Agents by Countries (2017-2019)
Figure Middle East and Africa Oral Antidiabetic Agents Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Saudi Arabia Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure United Arab Emirates Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Egypt Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Nigeria Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure South Africa Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Turkey Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Oral Antidiabetic Agents Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2017-2019)
Table Novartis AG Oral Antidiabetic Agents Financial Overview
Table Eli Lilly and Company Oral Antidiabetic Agents Financial Overview
Table Merck & Co., Inc Oral Antidiabetic Agents Financial Overview
Table Novo Nordisk A/S Oral Antidiabetic Agents Financial Overview
Table Johnson & Johnson Services, Inc. Oral Antidiabetic Agents Financial Overview
Table Teva Pharmaceuticals Pvt Ltd. Oral Antidiabetic Agents Financial Overview
Table F. Hoffmann-La Roche Ltd. Oral Antidiabetic Agents Financial Overview
Table Sanofi Oral Antidiabetic Agents Financial Overview
Figure Global Oral Antidiabetic Agents Revenue (Millions USD) and Growth Rate (2019-2027)
Table Oral Antidiabetic Agents Market Forecast by Regions (2019-2027)
Figure North America Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure United States Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Canada Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Mexico Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Europe Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Germany Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure France Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure UK Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Russia Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Italy Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Rest of Europe Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Asia-Pacific Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure China Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Japan Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Korea Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure India Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Southeast Asia Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure South America Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Brazil Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Argentina Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Columbia Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Rest of South America Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Middle East and Africa Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Saudi Arabia Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure United Arab Emirates Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Egypt Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Nigeria Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure South Africa Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Turkey Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Oral Antidiabetic Agents Market Forecast (2019-2027)
Figure Global Oral Antidiabetic Agents Forecast by Drug Class (2019-2027)
Figure Global Oral Antidiabetic Agents Market Share Forecast by Drug Class (2019-2027)
Figure Global Oral Antidiabetic Agents Forecast by Drug Class (2019-2027)
Figure Global Oral Antidiabetic Agents Forecast by Applications (2019-2027)
Figure Global Oral Antidiabetic Agents Market Share Forecast by Applications (2019-2027)
Figure Global Oral Antidiabetic Agents Forecast by Applications (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|